Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B66 and CYP2C1917 variants: a case report.

Pharmacogenomics - 1 Nov 2020

Stäuble Céline K, Lampert Markus L, Mikoteit Thorsten, Hatzinger Martin, Hersberger Kurt E, Meyer Zu Schwabedissen Henriette E

Abstract excerpt

We report the case of a patient with major depression treated with high-dose bupropion due to prior detected subtherapeutic blood concentrations at standard dosing. Pharmacogenetic panel testing identified the patient as a carrier of the CYP2B6*6 allele, which has been associated with reduced bupropion metabolism and decreased concentrations of the pharmacologically active metabolite hydroxybupropion....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents, Second-Generation
Share to Bupropion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2B6

Share to Cytochrome P-450 CYP2C19

Share to Depressive Disorder

Share to Hospitalization

Share to Recurrence

Share to Treatment Failure

Source

Identifiers

PMID: 33124517
DOI: 10.2217/pgs-2020-0087

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B6*6 and CYP2C19*17 variants: a case report.PMID 33124517Read ↗

Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.Semantic proximity Read ↗

Frequencies of CYP2C19 and CYP2D6 gene variants in a German inpatient sample with mood and anxiety disorders.Semantic proximity Read ↗

Pharmacogenetics testing for poor response to antidepressants: a transnosographic case seriesSemantic proximity Read ↗

Pharmacogenetics and the pharmacological management of depression.Semantic proximity Read ↗

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIsSemantic proximity Read ↗

Evaluating the Clinical Impact of CYP2C19 and CYP2D6 on Amitriptyline Outcomes in a Real-World Chronic Pain CohortSemantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updateSemantic proximity Read ↗

The association of COMT genotype with buproprion treatment response in the treatment of major depressive disorder.Semantic proximity Read ↗

Pharmacogenomic Characterization of Childbearing-Aged Individuals With Mood Disorders in a Tertiary Care Perinatal Mental Health Clinic.Semantic proximity Read ↗

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responsesSemantic proximity Read ↗

Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data.Semantic proximity Read ↗

Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.